CORTECS, the biotechnology group, yesterday signed a deal with the Spanish drug group, Ferrer, for the distribution of its osteoporosis treatment Macritonin in Latin America. The companies expect sales of around $20m (pounds 12.3m) for the drug in the region in the five years after registration.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments